A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Trial Profile

A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 May 2017

At a glance

  • Drugs MHAA 4549A (Primary) ; Oseltamivir
  • Indications Influenza A virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 06 May 2016 Primary endpoints updated and trial focus changed from TU, AR to TU, AR and PD. Also treatment arms changed fromm two to three according to ClinicalTrials.gov record.
    • 01 Feb 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017, as reported by ClinicalTrials.gov.
    • 01 Feb 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Jun 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top